The viewpoint paints a picture of a challenge that is 2-fold: a growing amount of people are injecting opioids in rural communities, which is an emerging risk factor for HIV transmission, and these communities often lack the infrastructure or resources to prevent, diagnose, and treat HIV.
As the United States continues to roll out initiatives to end the HIV epidemic by 2030, there are several challenges that stand in the way, including opioid injection in rural areas, according to a viewpoint appearing in JAMA.
Written by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Disease (NIAID), and Andrea M. Lerner, MD, a clinical associate at NIAID, the viewpoint paints a picture of a challenge that is 2-fold: a growing amount of people are injecting opioids in rural communities, which is an emerging risk factor for HIV transmission, and these communities often lack the infrastructure or resources to prevent, diagnose, and treat HIV.
“Although injection opioid use can lead to various infectious complications, including viral hepatitis, infective endocarditis, osteomyelitis, and skin and soft tissue infections, the epidemic of injecting opioids in rural areas of the United States is especially significant as an emerging risk factor for HIV transmission,” they write.
The pair reflected on recent outbreaks in Lawrence and Lowell, Massachusetts, and the notable 2014 outbreak in Scott County, Indiana, which was driven by injection of the extended-release formulation of oxymorphone. In response to the Scott County outbreak, in 2015, a public health emergency was declared in a state executive order and the county implemented efforts to slow the outbreak, including a temporary syringe exchange program and expanded access to HIV testing, treatment, and other services.
Throughout the entirety of the outbreak, more than 200 people in a community of approximately 4400 had been diagnosed with HIV. In its aftermath, the CDC pinpointed 220 counties across 26 states that they considered vulnerable to an outbreak. They focused on people who inject drugs and identified factors associated with the rate of acute hepatitis C virus infection as a proxy for unsafe injection drug use (IDU). Using these factors, the CDC created a vulnerability score for counties.
Among the 220 counties, the overwhelming majority were rural, and the top 10% were in Kentucky, West Virginia, and Tennessee. As of last year, less than a quarter of the counties had implemented needle and syringe exchange programs.
“If an outbreak of the size that occurred in Scott County, Indiana, occurred in each of the vulnerable counties without access to needle and syringe exchange programs, the number of new HIV diagnoses in the United States would increase substantially,” wrote Fauci and Lerner. “This lack of harm-reduction services threatens to reverse decades of progress and recapitulate the devastating effects that IDU-related transmissions had during the earlier years of the HIV epidemic in the United States.”
While the ultimate goal is to address the epidemic of injecting opioids, until the issue is controlled, the pair argues that it is crucial to aggressively address infectious complications of the epidemic. In addition to the implementation of needle and exchange programs, interventions include pre-exposure prophylaxis and antiretroviral therapy treatment to suppress viral load.
Reference
Lerner A, Fauci A. Opioid injection in rural areas of the United States [published online August 1, 2019] JAMA. doi: 10.1001/jama.2019.10657.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More